Project Grant R01HL172043
Award Date
9/15/24
Completion Date
6/30/28
Dollars Obligated
$814K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). The $491,056.01 award, effective May 20, 2025 through April 30, 2028, aims to examine the regulation and function of VPS34 in PAH, determine its impact on proliferation and survival of pulmonary artery...
This Project Grant award of $122,268.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of mitochondrial acid-sensing ion channel 1 (ASIC1) in pulmonary hypertension. The research, conducted at the University of New Mexico Health Sciences Center, aims to define the mechanisms by which the sigma-1 receptor regulates the subcellular localization of ASIC1, which affects pulmonary arterial...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The research aims to elucidate how MitoNEET regulates pulmonary artery smooth muscle cell function and mitochondrial bioenergetics, and to evaluate the potential of MitoNEET ligands as novel therapies for group 3 PH,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $760,708 to investigate the role of alternative polyadenylation (APA) in right ventricular (RV) fibrosis associated with pulmonary hypertension. The research aims to: Investigate the impact of the APA regulator CPSF6 depletion on the 3' UTR landscape and profibrotic gene expression in RV failure. Uncover the mechanism underlying CPSF6...
This Project Grant award of $498,000 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by National Jewish Health to investigate the role of RNA editing in pulmonary hypertension. The research aims to determine how the enzyme ADAR1-mediated RNA editing regulates the expression and function of the gene NOCT in pulmonary artery endothelial cells, and the impact on pulmonary hypertension development. The...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Leland Stanford Junior University provides $1,617,792 to investigate the role of the carboxylesterase 1 (CES1) enzyme in the pathogenesis of pulmonary arterial hypertension (PAH). The project aims to: 1) determine the mechanisms by which loss of CES1 results in metabolic reprogramming and lipotoxicity in pulmonary microvascular endothelial cells, 2) assess...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $658,885 to the University of Missouri System to investigate the role of the protein Response Gene to Complement 32 (RGC-32) in regulating endothelial-mesenchymal transition (EndoMT) and the development of pulmonary arterial hypertension (PAH). The research aims to determine the molecular mechanisms by which RGC-32 regulates EndoMT in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...